Ceftazidim - risultati della ricerca

pfizer ireland pharmaceuticals - avibactam sodium, ceftazidime pentahydrate - pneumonia, bacterial; soft tissue infections; pneumonia; urinary tract infections; gram-negative bacterial infections - antibatterici per uso sistemico, - zavicefta is indicated in adults and paediatric patients aged 3 months and older for the treatment of the following infections:complicated intra-abdominal infection (ciai)complicated urinary tract infection (cuti), including pyelonephritishospital-acquired pneumonia (hap), including ventilator associated pneumonia (vap)treatment of patients with bacteraemia that occurs in association with, or is suspected to be associated with, any of the infections listed above. zavicefta is also indicated for the treatment of infections due to aerobic gram-negative organisms in adults and paediatric patients aged 3 months and older with limited treatment options. dovrebbero essere prese in considerazione le linee guida ufficiali sull'uso appropriato degli agenti antibatterici..

Italia - italiano - AIFA (Agenzia Italiana del Farmaco)

glazidim

sandoz s.p.a. - ceftazidima - ceftazidima

Italia - italiano - AIFA (Agenzia Italiana del Farmaco)

starcef

f.i.r.m.a. s.p.a. - ceftazidima - ceftazidima

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

zavicefta polvere per concentrato per soluzione per infusione

pfizer ag - ceftazidimum, avibactamum - polvere per concentrato per soluzione per infusione - preparazione a secco: ceftazidimum 2 g per ceftazidimum pentahydricum, avibactamum 500 mg avibactamum natricum, natrii carbonas per vetro corrisp. sodio 145 mg. - malattie infettive - synthetika